The pharmaceutical industry is praised as a leader in high technology innovation and the creator of products that increase both longevity and quality of life for people throughout the world. Yet the industry is also reviled for its marketing and pricing practices and even its research and development priorities. This book uses the tools of economic analysis to explore the conflicting priorities and aims of the pharmaceutical industry, from both an American and worldwide perspective. This second edition includes six new chapters on emerging topics such as the broadened role of FDA regulations, alternative drugs or qnutraceuticals, q and biotechnology and other industries related to pharmaceuticals. Existing chapters are fully revised and updated to include new materials. The introduction is also updated to address the volatile pace of pharmaceutical innovation and how the pharmaceutical industry has responded to the emergence of managed care.See Research aamp; development RDUR (retrospective drug utilization review), 127- 128 Rebif, 90 Regulation of complementary and ... 300, 3011, 302 of dietary supplements, 286a292 of drug prices, 187 in Europe, 169, 238a249 for advertising, 248 centralized procedure for ... 46, 46t, 49a52 in Canada, 166 decision-making process insurance coverage and, 32a33 marketing department and, 33 developedanbsp;...
|Title||:||Pharmaceutical Economics and Policy|
|Author||:||Stuart O. Schweitzer|
|Publisher||:||Oxford University Press - 2007|